Abstract
Background and importanceABP 215 (MVASI) is the first approved biosimilar to Avastin (bevacizumab reference product, RP). ABP 215 presents an alternative and effective treatment option. ABP 215 is administered intravenously...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have